At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.